csh3 Antibody

What is CHSY3 and what tissue expression patterns should researchers expect?

CHSY3 (Chondroitin Sulfate Synthase 3) is an enzyme also known as Carbohydrate synthase 2, Chondroitin glucuronyltransferase 3, and several other aliases as reflected in database nomenclature. The protein has a calculated molecular weight of approximately 100 kDa and plays important roles in glycosaminoglycan biosynthesis pathways .

When designing experiments targeting CHSY3, researchers should account for its differential expression across tissues. According to expression data, CHSY3 is detected at relatively low levels in brain, cerebral cortex, uterus, and small intestine . This low abundance presents detection challenges that may require optimization of experimental protocols to achieve sufficient sensitivity. When planning experiments, especially those involving immunohistochemistry, these expression patterns should inform tissue selection and control strategies.

What applications are currently validated for commercial CHSY3 antibodies?

Commercial CHSY3 antibodies, such as the rabbit polyclonal antibody (catalog DF9378), have been primarily validated for Western Blot (WB) applications . This contrasts with other antibodies like CHRNB3 antibody (ab236745), which is validated for immunohistochemistry on paraffin-embedded tissues (IHC-P) and immunocytochemistry/immunofluorescence (ICC/IF) .

When planning experiments, researchers should consider that:

• Western Blot remains the primary validated application for CHSY3 detection

• Cross-validation may be necessary when attempting to use CHSY3 antibodies for non-validated applications

• Optimization of experimental conditions may be required for applications beyond Western Blot

• Species reactivity validation includes Human, Mouse, and Rat, with predicted reactivity for Bovine and Dog samples

How should researchers approach antibody validation to ensure experimental reproducibility?

Antibody validation is essential for experimental reproducibility. For CHSY3 antibody, researchers should implement a multi-step validation strategy:

• Literature cross-reference: Compare experimental outcomes with published results where possible

• Positive and negative controls: Include tissues with known expression levels (brain and small intestine as positive controls)

• Specificity testing: Consider knockout/knockdown models or blocking peptides

• Multiple detection methods: Validate findings using orthogonal techniques

• Batch consistency: Document lot numbers and perform quality control with each new antibody batch

The identification code RRID:AB_2842574 for CHSY3 antibody facilitates tracking of the specific reagent across publications, enhancing reproducibility . When citing antibody usage in publications, researchers should include catalog numbers, RRID identifiers, and specific experimental conditions to support reproducibility efforts.

What are the optimal storage and handling conditions for maintaining CHSY3 antibody activity?

While specific storage information for CHSY3 antibody isn't provided in the search results, general best practices for polyclonal antibodies should be followed:

• Storage temperature: Most antibodies should be stored at -20°C for long-term preservation and 4°C for short-term usage

• Aliquoting: To prevent freeze-thaw cycles, prepare small working aliquots

• Preservatives: Check if sodium azide or other preservatives are present, as these can interfere with certain applications

• Working dilutions: Prepare fresh working dilutions on the day of experiment

• Transportation: Maintain cold chain when transporting between laboratories

For CHSY3 antibody specifically, researchers should consult the manufacturer's datasheet for specific recommendations that may deviate from these general guidelines.

What methodological approaches should be considered when optimizing CHSY3 antibody for Western Blot applications?

When optimizing Western Blot protocols for CHSY3 detection, researchers should consider several methodological refinements:

• Sample preparation optimization: Given the 100 kDa size of CHSY3, use lower percentage gels (8-10%) for better resolution

• Transfer conditions: For high molecular weight proteins like CHSY3, extend transfer time or consider semi-dry transfer methods

• Blocking optimization: Test multiple blocking agents (BSA vs. milk) to determine optimal signal-to-noise ratio

• Antibody dilution range: Begin with the manufacturer's recommended dilution and test a range to determine optimal concentration

• Incubation conditions: Compare overnight 4°C incubation with shorter room temperature protocols

• Detection system selection: Choose between chemiluminescence, fluorescence, or chromogenic detection based on sensitivity requirements

A systematic optimization approach using a titration matrix can efficiently identify ideal conditions:

How do AI-based technologies contribute to antibody design, and what implications might this have for future CHSY3-targeted antibodies?

Recent advances in AI-based antibody design technologies are revolutionizing antibody development approaches:

• De novo sequence generation: AI models like IgLM can generate novel antibody sequences targeting specific antigens

• Structure prediction: Tools such as ImmuneBuilder can model antibody structures, facilitating screening before experimental validation

• Epitope targeting: AI can design antibodies against specific structural epitopes, potentially allowing targeting of functionally important regions of CHSY3

• Germline-based templates: AI methods can leverage germline gene templates to mimic natural antibody generation processes

In a recent validation study, researchers generated 1,000 de novo CDRH3 sequences using AI and successfully identified multiple antigen-specific antibodies with a promising hit rate of approximately 15% . This approach bypasses traditional antibody discovery challenges including the need for source samples with previous antigen exposure.

For future CHSY3 antibody development, AI approaches could:

• Design antibodies targeting specific domains of CHSY3 with greater precision

• Reduce development timelines compared to traditional hybridoma or phage display methods

• Generate antibodies with optimized properties for specific applications

• Create panels of complementary antibodies recognizing different epitopes

What strategies can researchers employ when working with low-abundance proteins like CHSY3?

CHSY3's low expression levels in tissues like brain and small intestine present detection challenges requiring specialized approaches:

• Sample enrichment methods:

  • Immunoprecipitation prior to Western Blot analysis

  • Subcellular fractionation to concentrate compartments where CHSY3 is localized

  • Protein concentration techniques for dilute samples

• Signal amplification systems:

  • Tyramide signal amplification (TSA) for immunohistochemistry

  • Enhanced chemiluminescence substrates for Western Blot

  • Biotin-streptavidin amplification systems

• Alternative detection strategies:

  • Proximity ligation assay (PLA) for detecting protein-protein interactions involving CHSY3

  • Mass spectrometry-based approaches for unbiased detection

  • RT-qPCR to assess mRNA levels as a proxy for protein expression

• Experimental controls:

  • Recombinant CHSY3 as positive control

  • Side-by-side comparison with tissues known to express higher levels

  • Calibration curves using purified protein standards

How can researchers differentiate between specific and non-specific binding when using CHSY3 antibody?

Differentiating specific from non-specific binding is crucial for accurate interpretation of CHSY3 antibody results:

• Blocking peptide competition: Pre-incubate antibody with the immunizing peptide to confirm binding specificity

• Multiple antibody validation: Use antibodies targeting different CHSY3 epitopes and compare binding patterns

• Genetic validation approaches:

  • CRISPR/Cas9 knockout controls

  • siRNA knockdown with quantitative assessment

  • Overexpression systems as positive controls

• Technical controls:

  • Isotype control antibodies to assess Fc-mediated binding

  • Secondary-only controls to evaluate background

  • Tissue panels including negative control tissues

• Analytical methods:

  • Quantitative band analysis in Western Blot with statistical validation

  • Comparison of observed molecular weight (100 kDa) with expected size

  • Evaluation of subcellular localization consistency with known biology

What considerations should guide the selection between monoclonal and polyclonal antibodies for CHSY3 detection?

Currently, commercial CHSY3 antibodies are available as rabbit polyclonal preparations , while other antibody types like anti-CCR3 are available as monoclonals . When deciding between antibody types, consider:

If pursuing custom antibody development for CHSY3, researchers might consider:

• Generating monoclonal antibodies for studies requiring absolute specificity

• Developing application-specific antibodies optimized for IHC or IP

• Creating epitope-specific antibodies targeting functional domains

• Utilizing AI-based design approaches to optimize antibody properties